StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM)

StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

CEL-SCI Stock Performance

Shares of CVM stock opened at $0.37 on Wednesday. The firm has a market cap of $24.33 million, a PE ratio of -0.63 and a beta of 0.65. CEL-SCI has a 12 month low of $0.36 and a 12 month high of $3.08. The company’s fifty day simple moving average is $0.63 and its 200-day simple moving average is $0.95. The company has a quick ratio of 0.18, a current ratio of 0.64 and a debt-to-equity ratio of 1.00.

Institutional Investors Weigh In On CEL-SCI

Several large investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after buying an additional 53,879 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of CEL-SCI by 29.9% in the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock valued at $202,000 after acquiring an additional 40,000 shares during the period. Thoroughbred Financial Services LLC increased its stake in shares of CEL-SCI by 140.9% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after purchasing an additional 80,001 shares during the last quarter. Plotkin Financial Advisors LLC bought a new stake in shares of CEL-SCI in the 3rd quarter valued at about $98,000. Finally, Black Diamond Financial LLC lifted its stake in CEL-SCI by 35.8% in the 2nd quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock valued at $84,000 after purchasing an additional 19,000 shares during the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.